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In  a  cooperative  agreement  starting  January  1995,  prior  to the  FDA’s  licensure  of  the  varicella  vaccine  on
March 17,  the  Centers  for  Disease  Control  and  Prevention  (CDC)  funded  the  Los  Angeles  Department  of
Health  Services’  Antelope  Valley  Varicella  Active  Surveillance  Project  (AV-VASP).  Since  only  varicella  case
reports were  gathered,  baseline  incidence  data  for  herpes  zoster  (HZ)  or shingles  was  lacking. Varicella
case reports  decreased  72%,  from  2834  in 1995  to 836  in  2000  at which  time  approximately  50% of  children
under  10  years  of age  had  been  vaccinated.  Starting  in  2000,  HZ  surveillance  was  added  to  the  project.  By
2002,  notable  increases  in  HZ  incidence  rates  were  reported  among  both  children  and  adults  with  a  prior
history  of  natural  varicella.  However,  CDC  authorities  still  claimed  that no increase  in  HZ  had  occurred
in any  US  surveillance  site.  The  basic  assumptions  inherent  to the  varicella  cost–beneﬁt  analysis  ignored
the  signiﬁcance  of  exogenous  boosting  caused  by  those  shedding  wild-type  VZV.  Also  ignored  was  the
morbidity  associated  with  even  rare  serious  events  following  varicella  vaccination  as  well  as  the morbidity
from  increasing  cases  of HZ  among  adults.  Vaccine  efﬁcacy  declined  below  80%  in  2001.  By  2006,  because
20%  of  vaccinees  were  experiencing  breakthrough  varicella  and  vaccine-induced  protection  was waning,
the CDC  recommended  a  booster  dose  for  children  and,  in  2007,  a  shingles  vaccination  was  approved
for  adults  aged  60 years  and  older.  In the  prelicensure  era,  95%  of  adults  experienced  natural  chickenpox
(usually  as  children)—these  cases  were  usually  benign  and  resulted  in  long-term  immunity.  Varicella
vaccination  is  less  effective  than  the  natural  immunity  that  existed  in  prevaccine  communities.  Universal
varicella  vaccination  has  not  proven  to  be cost-effective  as  increased  HZ  morbidity  has  disproportionately
offset  cost  savings  associated  with  reductions  in  varicella  disease.  Universal  varicella  vaccination  has
failed  to provide  long-term  protection  from  VZV  disease.
© 2012 Elsevier Ltd. Open access under CC BY license.. Introduction
The varicella-zoster virus (VZV) is a member of a family of
iruses known as Alphaherpesvirinae [genus and species: Vari-
ellovirus human herpesvirus 3 (HHV-3)] that upon initial exposure
auses varicella (chickenpox) as a primary infection. The initial
nfection is followed by a variable latency period, after which the
ifelong VZV in the dorsal root ganglia can subsequently reactivate
s herpes zoster (HZ), commonly known as shingles, a secondary
nfection. Following short-term safety and efﬁcacy clinical trials in
he US, the varicella vaccine, Merck’s Varivax®, was licensed for
se in children 12 months and older by the US Food and Drug
∗ Corresponding author. Tel.: +1 661 3052310; fax: +1 661 9444483.
E-mail addresses: gsgoldman@roadrunner.com, pearblossominc@aol.com
G.S. Goldman).
264-410X © 2012 Elsevier Ltd.  
ttp://dx.doi.org/10.1016/j.vaccine.2012.05.050
Open access under CC BY license.Administration (FDA) on March 17, 1995. On  July 12, 1996, the
US Centers for Disease Control and Prevention (CDC) published
the recommendations of its Advisory Committee on Immunization
Practices (ACIP) for universal varicella vaccination of all healthy,
susceptible children aged 12- to 18-months with a single 0.5-mL
vaccine dose [1].
Prior to the initiation of the universal varicella vaccina-
tion program in the US, most public health ofﬁcials assessing
the cost–beneﬁt of vaccination to protect against varicella
were principally concerned with data pertaining to clinical
chickenpox—largely ignoring the potential effects of this vac-
cine on the interrelated HZ epidemiology. In fact, three US
project sites (Antelope Valley, California; Travis County, Texas;
and West Philadelphia, Pennsylvania) were initially selected and
funded by the CDC to only perform active surveillance for vari-
cella in order to ascertain the effects of the varicella vaccine
on the population. Unfortunately, this limiting decision meant
 Vaccin
t
c
2
(
e
t
w
A
c
a
d
w
d
t
l
o
r
p
a
v
o
p
c
i
4
d
(
c
c
r
s
a
i
w
a
R
l
F
t
d
v
a
(
a
d
a
a
w
s
v
h
v
v
t
c
d
1
1G.S. Goldman, P.G. King /
hat the important baseline incidence data for HZ would not be
ollected.
. Methods
In 1995, The Los Angeles Department of Health Services
LADHS), Acute Communicable Disease Control (ACDC) unit
ntered into a cooperative agreement with the CDC to establish
he Antelope Valley Varicella Active Surveillance Project (AV-VASP)
hich immediately began conducting surveillance for varicella. The
ntelope Valley surveillance region consisted of approximately 35
ommunities, covering approximately 2000 square miles, located
bout 50 miles northeast of Los Angeles, California in the high-
esert plains, with a stable community of 300,000 residents (60% of
hich were found in the two principal cities of Lancaster and Palm-
ale). Approximately 300 different reporting units, representing all
he identiﬁable sources in the study region, submitted varicella case
ogs biweekly to the project. Each case log consisted of a listing
f the varicella cases encountered by a given reporting unit. The
eporting units comprised all known public and private schools and
reschool/daycare centers with enrollments of 12 or more children
nd approximately 90% of the public health clinics, hospitals, pri-
ate practice physicians, health maintenance organization (HMO)
fﬁces, correctional facilities, and large employers in the region.
With verbal permission of a parent/guardian, a structured tele-
hone interview was conducted regarding each reported varicella
ase under the age of 20 years old. To minimize recall bias, these
nterviews were usually conducted with the caregiver within
 weeks of the case report date. The interview provided detailed
emographic (to assist in detecting duplicate case reports), clinical
e.g., temperature of high fever if applicable, list of any pre-existing
onditions and/or medications, rating of severity of illness and
haracteristics of rash at the time of peak illness, duration of the
ash, etc.), and health impact data (e.g., days the parent and/or
tudent missed school or work). If other potential susceptible
nd exposed household members were identiﬁed, these were re-
nterviewed in another 4–6 weeks. The data from each interview
as entered into a computer database designed by project staff
nd implemented by Gary S. Goldman, PhD (Goldman), the project’s
esearch/Epidemiology Analyst from 1995 to November 2002.
In 2000, HZ was added to the surveillance and data was col-
ected in the same manner as previously described for varicella.
or HZ cases aged 20 years and over, only demographic informa-
ion was collected. In 2003, Goldman transported the AV-VASP
atabase, consisting of several hundred demographic and clinical
ariables for each case, to the CDC for their continued processing
nd analyses. Because of (a) minor differences in algorithms, and
b) slight differences and/or changes in handling veriﬁed and prob-
ble cases, varicella and HZ case counts reported in this review may
iffer slightly from those presented in AV-VASP published studies
nd annual project summaries to the CDC.
A case of varicella was deﬁned as illness with acute onset of
 diffuse papulovesicular rash without other known cause that
as diagnosed and/or reported by a licensed health care provider,
chool nurse, or parent. A case of HZ was deﬁned as a unilateral
esicular rash in a dermatomal distribution, diagnosed by a licensed
ealthcare provider. In 2004, veriﬁed HZ cases included all cases
alidated by medical record review in addition to the case inter-
iew.
Initially, varicella case reports decreased 80%, from 2934 in 1995
o 587 in 1999. Since varicella typically displays a 5-year annual
ycle in the Antelope Valley with a peak seasonal trend occurring
uring early winter and late spring, the reductions in varicella in
996 and 1997 occurred during a natural decline, following the
995 peak in this cycle, and were not the result of any early impacte 31 (2013) 1680– 1694 1681
of varicella vaccination on the study region. The reality was that
during the six surveillance years, 1995–2000, varicella vaccination
likely had begun to signiﬁcantly impact the otherwise naturally
decreasing incidence trend only during the latter 2 or 3 years. In
2000 the number of varicella case reports increased to 836, which
was  still a 72% decrease relative to a naturally occurring cyclical
peak in wild-type varicella cases reported in 1995.
Prior to the start of surveillance year 2000, Goldman recom-
mended that HZ-case data be added to the surveillance based
on anecdotal reports from long-time public school nurses who
reported observing cases of childhood HZ that they had previously
rarely, if ever, encountered. The CDC accepted the renewal grant
application that included the HZ proposal. Thus, starting in 2000,
VASP performed active surveillance for both varicella and HZ. The
largest HMO  (Kaiser—serving an estimated 30% of the study popu-
lation) began regularly reporting HZ cases in 2002 based on ﬁltering
International Classiﬁcation of Disease, Ninth Revision (ICD-9) codes
for HZ-associated patient visits. Increased surveillance for adult HZ
with the inclusion of skilled nursing facilities, dermatology prac-
tices, and internal medicine practices was proposed starting in
2005. Thus, HZ counts were signiﬁcantly under-reported in years
prior to 2005.
The study results presented in this review are primarily from
this Antelope Valley population, which experienced relatively high
levels of varicella vaccine uptake/coverage. Because the surveil-
lance was active (and not passive), AV-VASP managed to collect
100% of the varicella case logs biweekly from all of the reporting
units participating in the AV-VASP [2].  Moreover, the surveillance
was  able to detect sensitive trends early in the universal varicella
vaccination program because of four contributing factors: (1) the
survey region was relatively isolated geographically with few res-
idents seeking healthcare or attending schools outside the region,
(2) the population was relatively stable, (3) there was  no sampling
(whereas, some sampling occurred in the other two  CDC-funded
sites), and (4) the existence of two  ascertainment sources (schools
and healthcare providers) allowed the use of capture–recapture
statistical methods to derive ascertainment-corrected counts of
varicella and HZ case reports.
The AV-VASP data collection was uninterrupted and surveil-
lance activities remained relatively stable through 2002. However,
the 302 adult HZ cases reported to AV-VASP in 2003, representing
an 18% decrease from the 368 cases reported in 2002, was  an arti-
fact associated with the lack of the AV-VASPs sending a reminder
via fax to each surveillance unit failing to submit a timely biweekly
report (as had been previously done by an automated fax system
implemented by the Research Analyst from 1995 through 2002).
AV-VASP operations and reporting patterns were again temporar-
ily affected when a new Project Director was installed in 2004
following the resignation of the initial Project Director.
3. Early-determined HZ incidence rates were censored
By 2000, exogenous exposures to natural varicella (producing
immunologic boosts) were dramatically reduced, especially after a
marked decline in varicella incidence beginning in 1999 [2].  After
2 years of active HZ surveillance (2000 and 2001), Goldman noted
that the number of HZ case reports had maintained or increased
in every adult age category except elderly adults aged 70 years
and older (Fig. 1) [3].  Using the paired t-test, the 28.5% increase
in HZ case reports from 158 in 2000 to 203 in 2001 for ages
20–69 years was statistically signiﬁcant (p < 0.042; t = 2.95, dF = 4)
(Fig. 1). Also, the HZ incidence rate was  low among vaccinated chil-
dren under 10 years of age. However, the ascertainment-corrected,
true HZ incidence rate of 307/100,000 person-years (p-y) during
2000–2001 [3] and 446/100,000 p-y during 2000–2003 [4] among
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In 2004, AV-VASP and CDC took issue with Goldman’s presen-ig. 1. Number of adult HZ case reports by 10-year age category, Antelope Valley
ASP, 2000 and 2001 [3,39].
hildren having a previous history of natural varicella exceeded
hat of any rates published in historical studies. Authorities within
he CDC and AV-VASP were under the false impression that such
accination-program related trends would take “15–20 years to
anifest themselves”. They suggested that perhaps HZ incidence
ates in the study population had always been unusually high, or
ere subject to greater diagnostic awareness, i.e., physicians were
iagnosing more cases of HZ in the Antelope Valley region because
V-VASP was conducting active surveillance in that region. How-
ver, if this were true, AV-VASP would have expected to ﬁnd that
Z incidence among vaccinated children was also unusually high
nd this was not the case. Consequently, the lower HZ rate in
he vaccinated children and the expected rate in the 10–19 years
ge category negated the “unusually high” and “greater diagnostic
wareness” hypotheses.
The next stated challenge was that the high HZ incidence rate
eported among children with a prior history of varicella in the
ostvaccine period was due to bias associated with diagnostic
rror. However, since HZ was supposedly a rare disease in chil-
ren (at least in the pre-licensure era), affecting 0.74 cases per
000 children, it was unlikely that a physician would choose HZ
s a differential diagnosis over more commonly occurring alterna-
ive diagnoses (e.g., herpes simplex virus—HSV, contact dermatitis,
nd impetigo).
While these observations were indeed preliminary and would
equire conﬁrmation in other communities over a suitable longitu-
inal time period, AV-VASP and CDC opposed publication of these
ndings despite the reported HZ incidence rates having observa-
ion times (in terms of p-y) that were either similar to, or exceeded,
hat of other published studies by Guess et al. [5],  Donahue et al.
6],  Hope-Simpson [7],  and Ragozzino [8].
After 6 years of varicella surveillance (1995–2000), the opti-
ism of VASP/CDC was summarized as:
Varicella disease has declined dramatically in surveillance areas
with moderate vaccine coverage. Continued implementation
of existing vaccine policies should lead to further reductions
of varicella disease in these communities and throughout the
United States [2].
Yet, after 7 years (2000–2006) of HZ surveillance, the CDC
ould only report, “Data are inconclusive regarding an effect of
he varicella vaccination program on herpes zoster epidemiology”
9].  A CDC study which found no increase in HZ incidence [10]
as severely criticized since it was conducted in a population
here varicella-vaccination coverage was not widespread in the
ommunity [11]. Two additional studies in 2011 reported no evi-
ence of the universal varicella vaccination program contributing
o increases in HZ in the US [12] and Canada [13]. But, both of
hese studies had serious methodological limitations including bias
rom not being conducted in a closed population since the data
ere acquired from a medical claims database and an adminis-
rative database, respectively—data from which individuals maye 31 (2013) 1680– 1694
disenroll causing their health history to cease to be tracked. Addi-
tionally, the Leung et al. study utilized US medical claims records
from Marketscan® databases with HZ ICD-9 codes which could not
be validated through record reviews, though they were thought to
be 85% or more accurate [12].
Thus, all the positive trends from the AV-VASP study data
concerning single-dose vaccination for varicella, and, then, the
deleterious trends that suggested the adoption of a two-dose
varicella vaccination program (because of the observed waning
immunity in a population with widespread vaccination coverage
and because an increasing number of vaccinees were experienc-
ing breakthrough varicella), were published in a timely manner
[14–30],  usually co-authored by Dr. Jane F. Seward [who ini-
tially headed the Varicella Epidemiology and Surveillance Division
(VESD) of the National Immunization Program (NIP), and later
served as Deputy Director, Division of Viral Diseases in the National
Center for Immunization and Respiratory Diseases (NCIRD), CDC,
Atlanta, GA], Dr. Aisha O. Jumaan (NIP and Division of Viral Dis-
eases in the NCIRD, CDC), and Dr. Laurene Mascola (co-principal
Investigator AV-VASP, Los Angeles County Department of Health
Services, Los Angeles, CA).
3.1. The AV-VASP opposed publication of unwelcome HZ  data
In November 2002, Goldman resigned from AV-VASP to objec-
tively publish the other half of the VASP ﬁndings regarding HZ
incidence rates and the use of capture–recapture methodology to
correct for under-reporting. While all trends promoting one-dose
and then two-dose protocols were encouraged and readily ﬁnalized
for presentation at various symposiums and/or published by AV-
VASP, unwelcome adverse outcomes concerning relatively high and
increasing HZ incidence in the Antelope Valley community with
moderate vaccination coverage were seemingly censored. Three
manuscripts that Goldman had authored and which had been given
such “low priority” by AV-VASP and CDC that they were unlikely to
ever receive a formal internal review, were submitted to the journal
Vaccine. Goldman, as a courtesy, informed AV-VASP and CDC of his
intent to publish these manuscripts. Shortly thereafter, Dr. Laurene
Mascola of the ACDC Unit of LADHS induced the Los Angeles County
Legal Department to demand, in a letter dated April 10, 2003, that
Goldman “cease and desist publication” of these manuscripts in a
medical journal.
Goldman secured the services of a knowledgeable attorney,
who, after reviewing the facts, advised the Los Angeles County’s
legal counsel: “(a) if your client persists in its efforts to restrain
his ﬁndings, (b) if his ﬁndings enhance the public health, safety,
and welfare, (c) if by seeking to restrain him from imparting valu-
able information concerning the lack of safety and effectiveness
of the pharmaceutical being reported upon, and (d) if the County
of Los Angeles has in any way been enriched by its participa-
tion in any study the results of which it seeks to restrain in this
manner or any other manner whatsoever,” then there would be
follow-up litigation under both the State and Federal False Claims
Acts.
The county dropped its opposition and the manuscripts
were peer-reviewed and accepted for publication as three
consecutive articles in the journal Vaccine in October 2003
[3,31,32].
3.2. AV-VASP and CDC ﬁnally conﬁrm Goldman’s preliminary HZ
incidence ratestation of HZ data and authored a criticism [33] of the three studies
published in Vaccine by Goldman. Goldman’s rebuttal response
demonstrated those criticisms to be invalid on every account [34].
G.S. Goldman, P.G. King / Vaccine 31 (2013) 1680– 1694 1683
Table 1
Comparison of cumulative HZ incidence rates (cases per 100,000 p-y) derived by VASP/CDC (2000–2006) and Goldman (2000–2003).
Category (age in years) Cumulative 2000–2006 Cumulative 2000–2003 HZ incidence rate [4] Ascertainment-corrected HZ
incidence ratea
HZ incidence rate [36] (95% C.I.) Sample size Uncorrected HZ incidence rate
(95% C.I.)
Sample size
Vaccinated, 1–9 19 (15–25) 51 14 (9–21) 21 28
Natural Varicella, 1–9 239 (193–295) 84 223 (180–273) 94b 446
Natural Varicella 10–19 69 (61–77) 305 61 (51–72) 131 122
C.I. 34
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2a The reporting completeness of HZ case reports was  determined to be 50% (95% 
b The number of shingles case reports included those veriﬁed (with interview co
ase  or case’s parent/guardian could not be interviewed).
urther, the additional analyses that Goldman had performed using
pdated VASP data from 2000 to 2003 were published in 2005/2006
n The International Journal of Toxicology [4,35].
Ironically, in 2009, VASP and CDC published updated estimates
f HZ incidence rates derived from AV-VASP case reports from
000 to 2006 [36]. The study methodology used by Civen et al.
as similar to that shared by Goldman with the AV-VASP staff in
002 and detailed in 2003 [3] and 2005 [4] publications. Moreover,
here were virtually no differences between the unadjusted cumu-
ative 2000–2003 HZ incidence rates reported by Goldman [4] and
he unadjusted cumulative 2000–2006 HZ incidence rates jointly
eported later by VASP and CDC (Table 1). The ascertainment-
orrected HZ incidence rates reported by Goldman (discussed in
ore detail in Section 4) were approximately double the unad-
usted rates since capture–recapture demonstrated that AV-VASP
ad a 50% reporting completeness of HZ cases (Table 1).
Since medical costs associated with VZV were 4–5 times higher
or those reactivating with HZ compared to those contracting vari-
ella, only modest increases in the number of HZ cases would
e sufﬁcient to outweigh any beneﬁts caused by reductions in
aricella incidence, morbidity, and mortality [37] (Table 2). The
o-principal investigators of AV-VASP were well aware of this con-
ern. A supportive HZ-to-varicella cost ratio of 4.5 was reported in
 Canadian province based on an analysis of only the direct costs
uring 1992–1996 [38].
.3. Baseline crude and true HZ incidence rates in the Antelope
alley region
In 2000, the CDC had commissioned the AV-VASP to conduct a
pecial survey among students (principally aged 10–14 years) in
ublic middle (7/8th grade) schools within the Antelope Valley
tudy population to determine the percentage of students sus-
eptible to varicella. Interestingly, the susceptibility results of this
ntelope Valley adolescent study closely mirrored those of another
tudy population in Kentucky [31].
This adolescent survey was modiﬁed by Goldman (with the
pproval of the co-principal investigators) to collect information as
able 2
re-licensure medical costs for herpes zoster are 4–5 times higher than the costs for
aricella.
Description Varicella (Chickenpox) Herpes zoster (Shingles)
Number of cases 4 milliona 1 million
Hospitalizations 11,000a 22,000b
Deaths 100a 400b
Medical costs $275 million $1.1 billionc
a Based on 5-year data prior to vaccine licensure.
b Miller E, Marshall R, Vurdien J. Epidemiology, outcome and control of varicella-
oster infection. Rev Med  Microbiol 1993;4(October (4)):222–30.
c Yawn BP, Itzler RF, Wollan PC, Pellissier JM,  Sy LS, Saddier P. Health care utiliza-
ion and cost burden of herpes zoster in a community population. Mayo Clin Proc
009;84(September (9)):787–94.–65%) among those aged 5–19 years during 2000–2001.
ed by phone) as well as those probable (reported by a physician, even though the
to whether the student had had shingles (HZ) and, if so, at what age.
By ignoring any HZ cases reported as occurring in the most recent
5 years (1996–2000) on the 4216 returned questionnaires, it was
possible to derive a cumulative incidence rate of HZ among chil-
dren who  were under 10 years of age during the period prior to the
start of the universal varicella vaccination program. The cumulative
1987-to-1995 crude HZ incidence rate among all children (includ-
ing those still susceptible to varicella) was 72 cases/100,000 p-y
which closely agreed with the crude rate of 68 cases/100,000 p-y
reported by Guess et al. [5] and the crude rate of 74 cases/100,000 p-
y reported by Hope-Simpson in Cirenchester, England [7].  The true
incidence rate of HZ was  roughly double, or 145 (95% C.I. 86–228)
cases/100,000 p-y (18 cases/12,457 p-y) among only those children
with a previous history of varicella—since about 50% of the chil-
dren, principally aged 0–4 years, were still susceptible to varicella
infection and hence, not candidates for HZ reactivation. Again, this
derived true HZ rate was  similar to the HZ rate of 133/100,000 per-
son years aged <14 years in the population-based result reported in
1995 by Donahue in a Harvard Community Health Plan study [6].
These ﬁndings provided a quantitative rebuttal response to
AV-VASP co-principal investigators’ challenge that, historically,
perhaps the HZ rate among children in the Antelope Valley region
had always been unusually high relative to children in other pop-
ulations.
Based on the data collected from the adolescent surveys, Gold-
man  wrote a paper detailing both the varicella susceptibility results
and the baseline HZ incidence rates. The portion of the paper con-
cerning varicella susceptibility was published virtually word for
word with its authorship also attributed to the AV-VASP and CDC
staff (Maupin T, Goldman G, Peterson C, Mascola L, Seward J, Jumaan
A. Varicella susceptibility among adolescents in an active surveil-
lance site. In: 36th National Immunization Conference of the CDC,
Denver, CO; May  1, 2002). However, the AV-VASP project direc-
tor demanded that the analysis and narrative pertaining to HZ be
entirely deleted. The HZ incidence results would also be absent
from the VASP’s annual report—never to be discussed or considered
in a separate publication. Shortly after leaving AV-VASP, Gold-
man  published the adolescent study data and results—presenting
both the number of adolescents still susceptible to varicella and
the Antelope Valley region’s baseline HZ incidence rates prior to
widespread varicella vaccination [3].
3.4. Recurrent HZ incidence rate
The recurrent HZ incidence rate (i.e., the rate among individuals
that reported having a second case of HZ that occurred six or more
months following a ﬁrst case) in the Antelope Valley study region
was  computed by dividing the number of reported second cases
of HZ by the observation time that accumulated from the num-
ber of ﬁrst-time-reported HZ cases. From January 2000 through
April 2002 (2 years and 4 months) the recurrent HZ incidence rate
in the AV-VASP was 2440/100,000 p-y (95% C.I. 1220–4374) based
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n 11 HZ recurrences during an observation time of 450 p-y. AV-
ASP did not permit follow-up of the 11 recurrent HZ cases among
dults to ascertain if they had pre-existing medical conditions or
ere immunocompromised. This post-vaccine recurrent HZ inci-
ence rate was 3.3-fold (95% C.I. 1.0–10.3) higher than that of the
re-licensure era rate reported by the 2-year Harvard Community
ealth Plan study by Donahue et al. of 744/100,000 p-y (95% C.I.
03–1907) based on 4 recurrent HZ cases (3 of which were individ-
als that were HIV positive) during an observation time of 538 p-y
6].
.5. Mounting evidence from preliminary HZ surveillance
onducted by AV-VASP during 2000–2002 that supported the
igniﬁcant role of periodic exogenous exposures
Certainly, because of the relatively low observation time, the
onﬁdence interval was wide with respect to the recurrent HZ inci-
ence rate. Given the small number of recurrent HZ case reports
nd low observation time, this wide conﬁdence interval was  not of
ajor importance. However, the recurrent HZ incidence rate, being
elatively high compared to a pre-vaccine rate, was  one more fac-
or contributing to the mounting evidence that individuals, who
eceived periodic exogenous exposures from those shedding VZV,
eceived signiﬁcant subclinical boosts to cell-mediated immunity
hat helped to postpone or suppress their reactivation of HZ.
Thus, the mounting evidence came to include
The high recurrent HZ incidence rate of 2440/100,000 p-y relative
to the 744/100,000 p-y reported by Donahue et al. [6].
The high HZ incidence rate among children under 10 years of
age with a prior history of natural varicella of 307/100,000 p-y
during 2000–2001 [3] and 446/100,000 p-y during 2000–2003
[4]—higher than any other historical rates.
The 18% overall increase in adult HZ from 2000 to 2001; case
counts maintained or increased in every age category except
elderly adults 70+ years (Fig. 1); the 28.5% increase in HZ reports
among adults 20–59 years was statistically signiﬁcant (p < 0.042).
The 56% increase in HZ case reports among adults 20 years of age
and older from 236 in 2000 to 368 in 2002 [39].
Baseline prevaccine cumulative 1987–1995 true HZ incidence
rate of 145/100,000 p-y among children under 10 years of age
[31].
. Capture–recapture ascertainment-correction
The incidence rate estimates presented in most epidemiologic
tudies are extremely poor, missing 10–90% of the cases, with a high
egree of variation [40–43].  This “missing cases” reality is even true
f active surveillance where the attempt is made to count every
ase via comprehensive data collection from nearly all possible
ontributing sources. Without correcting for under-reporting, the
V-VASP incidence rates for varicella (and HZ) would simply reﬂect
he level of case reporting and the unadjusted counts of varicella
and HZ) would contribute to the calculation of incidence rates that
ould not be comparable to other studies—especially those having
ither much lower or much higher levels of case ascertainment.
.1. The National Health Interview Survey (NHIS) criterion
tandard validated the accuracy of using two-source
apture–recapture methodsDue to difﬁculty in interpreting the population incidence results
hen the data consists of report counts that are incomplete
since ascertainment and enumeration of cases via active surveil-
ance is never 100%), the AV-VASP utilized capture–recapturee 31 (2013) 1680– 1694
methodology with the healthcare providers and the schools serv-
ing as two independent ascertainment sources. To determine
whether or not the capture–recapture estimates were accurate
and the various capture–recapture assumptions of independence,
100% data linkage, and a closed population were valid, the 1995
ascertainment-corrected incidence rates in the age categories
1–4, 5–9, 10–14, and 15–19 years of age were compared with
the gold standard, the 1990–1994 NHIS annual varicella inci-
dence rates in the US. The AV-VASP reporting completeness of
varicella cases aged 1–19 years was estimated at 46%, yield-
ing an ascertainment-corrected incidence rate of 50.9/1000. The
1990–1994 NHIS varicella incidence rate of 53.2/1000 in this
same age group was  4.3% higher [32]. Accepting the fact that
some local variation in varicella incidence might be expected, the
ascertainment-corrected rates for the Antelope Valley reasonably
approximated those national rates reported by NHIS. This agree-
ment conﬁrmed the validity of using this statistics-based approach
to correct for under-reporting in the Antelope Valley surveillance
region.
The ascertainment-corrected varicella incidence rates in the AV-
VASP for age categories 1–4, 5–9, and 10–14 years of age were lower
than the incidence rates reported by NHIS. This may  be due to the
fact that schools often require a healthcare provider’s written notice
to excuse an absent student; thereby, creating a positive depen-
dence of school and healthcare provider ascertainment sources.
Under this scenario, the capture–recapture estimates likely rep-
resented lower bound values of the true varicella incidence rates
[44].
4.2. Importance of using capture–recapture to obtain
ascertainment-corrected counts for HZ cases reported to AV-VASP
Because the same reporting units that reported varicella cases,
also reported HZ cases, it would be logical to presume that reporting
completeness for both diseases was  similar. This indeed proved to
be true as shown in the following quantitative capture–recapture
assessment: Consider that during 2000–2001, among unvaccinated
children and adolescents aged 5–19 years, the schools reported 54
HZ cases and the healthcare providers reported 91 cases of HZ.
Of these 145-case reports, 19 were duplicates. Although all 54
cases that were reported by schools sought attention from health-
care providers participating in the active surveillance project, only
19 (35%) were reported to the VASP by healthcare providers.
Capture–recapture methods estimated the reporting completeness
was  50% (95% C.I. 34–65%) [4].
In Table 1, taking into account the 50% under-reporting of HZ
cases, the ascertainment-corrected HZ incidence rates shown in the
right-most column are double that of the corresponding unadjusted
rates in the adjacent column. Interestingly, the ascertainment-
corrected HZ incidence rate of 28/100,000 p-y among vaccinated
children aged 1–9 years (Table 1) compares with the rate reported
by Tseng et al. of 27.4/100,000 p-y (95% C.I. 22.7–32.7) based on
172,163 vaccinated children with overall follow-up of 446,027 p-y,
among children less than or equal to 12 years of age [45].
In 2003/2004, at two different conference presentations, Civen
et al. reported the crude cumulative (2000–2003) HZ incidence
rates using unadjusted counts of HZ cases reported to the AV-
VASP making the incorrect assumption that AV-VASP had achieved
100% case ascertainment [46,47]. Thus, the reported post-licensure
crude incidence rates of 40/100,000 p-y among children aged
<10 years (of which the large majority had been vaccinated) and
45/100,000 p-y among individuals aged 10–19 years [47] seemingly
lead to the conclusion that HZ incidence in the AV-VASP study
population was low and there was  negligible difference between
HZ incidence rates among vaccinated and unvaccinated cohorts.
As previously noted, the failure of the AV-VASP study to perform
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scertainment-correction for the HZ case-report counts as was
one in the Goldman study [4],  precluded valid comparisons of
Z incidence rates reported in other studies having higher report-
ng completeness. McCarty et al. “strongly urge that all rates be
eported only after formal evaluation and adjustments for under-
scertainment have been completed” [42].
Furthermore, the HZ incidence rates widely differed among
accinated and unvaccinated cohorts of children aged 1–9 years.
herefore, AV-VASPs reporting a single mean HZ incidence of a
imodal distribution in this age category was statistically invalid
nd concealed the reality that the HZ incidence rate among chil-
ren with a previous history of varicella was signiﬁcantly higher
han (a) incidence rates reported in other historical studies as well
s (b) the incidence rate reported in the next 10- to 19-year age
ategory.
. Periodic exogenous exposures provided subclinical
oosts to immunity
Prior to and during the early years of the universal varicella
accination program, a controversy existed as to whether periodic
xogenous exposures caused an immunologic boost that helped to
uppress or postpone the reactivation of HZ in those children and
dults that previously had a history of natural (wild-type) varicella
48,49]. Historical HZ incidence studies reported trends of HZ rates
hat increased with age.
In 1965, Dr. Hope-Simpson was ﬁrst to suggest, “The peculiar age
istribution of zoster may  in part reﬂect the frequency with which
he different age groups encounter cases of varicella and because of
he ensuing boost to their antibody protection have their attacks of
oster postponed” [7].  However, prior to 1999, only limited studies
xisted that supported this hypothesis. For example, in 1983, Arvin
t al. noted a boost in cell-mediated immunity (CMI) in 71% of adults
ho were exposed to varicella patients in the family [50]. In 1995,
erada et al. reported that Japanese pediatricians aged 50–69 who
eceived multiple VZV exposures, demonstrated HZ incidence rates
ne-half to one-eighth that of the general population [51]. Geshon
t al. in 1996 showed an immunologic boost that reduced the risk
f HZ among leukemic children by reexposure to VZV, either by
accination or by close exposure to varicella [52]. A 1998 study by
olmon found that pediatricians who had a greater incidence of
xposure to VZV had lower rates of HZ than psychiatrists who had
he lowest VZV exposure rates [53]. More recent studies by Thomas
t al. [54] and Salleras et al. [55] have also demonstrated that re-
xposure to VZV via contacts with children was associated with
eduction in the risk of HZ in adults.
A number of studies have noted paradoxically that women, who
enerally have greater contacts with children, exhibit higher HZ
ncidence than men. This relationship of a higher female-to-male
ate ratio experiencing HZ has been observed in diverse age groups
rom children and adolescents to older adults. The existence of a
rue gender difference in response to the reactivation of VZV as
Z, does not negate this fact: Regardless of gender, in any age
ategory, when the number of exogenous exposures is increased,
Z incidence decreased; conversely, in the absence of exogenous
xposures HZ incidence increased.
As the Antelope Valley region (and likely other communities)
egan experiencing 70% or more declines in varicella cases relative
o the pre-licensure era, exogenous exposures to natural varicella
ecame rare and it became increasingly apparent that both the efﬁ-
acy and the safety of varicella vaccination had been confounded
nd overestimated in earlier clinical trials where vaccinees had
een immunologically boosted by periodic exogenous exposures
o children with natural varicella—especially those studies con-
ucted in years having peak varicella transmissions due to seasonal
pidemics.e 31 (2013) 1680– 1694 1685
By 2006, because vaccinated children were increasingly expe-
riencing breakthrough varicella and failure of vaccine-induced
disease protection to last “indeﬁnitely” [24], the CDCs ACIP ignored
the obvious failure of the assumptions that had been used to jus-
tify the initial vaccination program and, instead of stopping the
one-dose universal varicella vaccination program, recommended
that children receive two  varicella doses—“the ﬁrst dose should
be administered at age 12–15 months, and a newly recommended
second dose should be administered at age 4–6 years” [56]. Further,
modeling revealed the potential for two-dose coverage to cause an
increasing shift of varicella to older-age children and adults, where
morbidity and mortality are increased [57]. In an effort to partially
counteract the negative effects of the now two-dose universal vari-
cella vaccination program on the epidemiology of HZ in adults, a
shingles vaccine (Merck’s Zostavax®) was recommended for adults
60 years and older in 2007 [58].
6. HZ incidence rates increased during the universal
varicella vaccination program
6.1. Models predict “major epidemic” of HZ
Brisson et al. report that exposure to varicella is highly protec-
tive against HZ. Modeling this VZV transmission for the US, the
study concluded, “Mass varicella vaccination is expected to cause a
major epidemic of herpes-zoster, affecting more than 50% of those
aged 10–44 years at the introduction of vaccination” [59]. Brisson
et al. continued:
Eliminating varicella in a country. . .the size of the U.S. (280 mil-
lion) would prevent approximately 186 million cases of varicella
and 5,000 deaths over 50 years. However, our model predicts
that eliminating varicella transmission could generate an extra
21 million cases of herpes zoster resulting in 5,000 deaths [59].
Another age-structured transmission dynamic model for the UK
reported, “Routine infant varicella vaccination is unlikely to be cost-
effective and may  produce an increase in overall morbidity” [60].
6.2. Studies in communities with moderate varicella vaccination
coverage that reported increasing HZ medical costs and incidence
Since the introduction of the varicella (chickenpox) vaccine in
the US, there has been the concern that diminishing exposure
to natural varicella could cause reactivations of the latent VZV
as HZ. Patel et al. report that the net hospitalization costs for
complications of HZ have increased by more than $700 million
annually by 2004 for adults 60 years and older [60]. While rates
of varicella-related hospital discharges decreased, there was  an
increase in HZ-rated hospital discharges, disproportionately among
older adults [61].
From 2000 to 2001, reported HZ cases aged 20 years and older
increased 18% in the AV-VASP (Fig. 1) [39] and this compares to the
22.5% annual increase reported in Massachusetts by Yih et al. from
1999 to 2003 [62]. A large 34% increase in HZ reports to AV-VASP
was  noted from 2001 to 2002 when an HMO (Kaiser) began report-
ing to the AV-VASP. This may  have contributed to the high mean
increase in HZ reports of approximately 28%/year among adults
20 years and older from 2000 to 2002 [39]. However, the AV-VASP
reported a similar increase of 28% during 2006–2007 among adults
aged 50 years and older as well as a larger 38% increase in HZ inci-
dence among adults aged 50–59 years [63]. From 2000 to 2006, the
incidence among those aged 10–19 years approximately doubled
[63].
Thus, two  population-based studies, conducted in two differ-
ent, stable communities where (1) there was moderate varicella
1686 G.S. Goldman, P.G. King / Vaccine 31 (2013) 1680– 1694
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Fig. 2. Relationships between varicella incidence and estimated HZ incid
accination coverage (with greater than 50% of children under
0 years of age vaccinated) and (2) dramatic 70% reductions in wild-
ype varicella incidence rates relative to the pre-licensure era rates,
eported signiﬁcant HZ increases 4–8 years after the start of the
niversal varicella vaccination program [39,62,63].
The inter-relationship of varicella incidence and expected HZ
ncidence rates is not very complicated as shown in Fig. 2. Ten
ears following licensure of varicella vaccine, varicella incidence
primarily in children, since adult varicella cases have only a negli-
ible contribution) has been reduced to 10% of the prevaccine rate.
 second varicella dose administered to children 4–5 years of age
erves to sufﬁciently boost this cohort for the next 5 years such
hat varicella breakthrough disease and/or HZ reactivation stay in
heck at low levels among children—declining over time from the
rue pre-licensure HZ incidence rate of about 1.4 cases/1000 p-
 to 0.4 cases/1000 p-y based on HZ reports to AV-VASP. The
scertainment-corrected HZ incidence rate among 10- to 19-year
lds approximately doubled from 2000 to 2006 based on AV-VASP
eports (Fig. 2). Ten years following licensure, virtually the entire
ohort of children has been administered varicella vaccine which
as boosted immunity that was previously provided in the pre-
accine era by exogenous exposures to natural varicella. The curve
epicting the adult (20–59 years) HZ incidence rate is estimated
y considering (a) under-ascertained HZ reports to AV-VASP, (b)
nnual reported increases in adult HZ case reports, and (c) plausible
imits of HZ incidence in the near absence of exogenous boosting.
he adult HZ incidence rate increased over time from the pre-
icensure HZ incidence rate of about 3/1000 p-y to 5/1000 p-y as
xogenous exposures substantially diminished (Fig. 2).
Other studies with conﬂicting conclusions that reported no HZ
ncreases [10,12,13] should not be hastily judged as contradictory
hen the underlying limitations in these studies are understood,
.g., (a) the study was conducted in a community having limited
aricella vaccination coverage [10], and (b) data was  extractedin Antelope Valley community adopting universal varicella vaccination.
from a medical database that failed to track the health history of
individuals that disenrolled and whose enrollment distribution by
age differed from that of the true population [12,13]. Additionally,
though the CDC has suggested that other long-term studies con-
ducted prior to the start of universal varicella vaccination have
demonstrated increasing HZ incidence trends, these studies (dis-
cussed in detail in Section 8) document much smaller annual
percentage changes on the order of 1–3% which are attributed to
studying an aging population.
Finally, it is constructive to consider additional reasons why sev-
eral other studies conducted among adult populations reported low
annual percentage increases in HZ incidence rates ranging from
5.6 to 9.1% [64–66] relative to the high annual rates reported by
the AV-VASP [61,63] and Yih et al. [62] studies. The lowest annual
percentage HZ increase, 5.6%, reported in Olmstead County, Min-
nesota between 1996 and 2001 [64], may  be attributed, in part, to
an aging population and minimal impact of varicella vaccination
in those years. Minnesota did not require varicella vaccination for
students entering kindergarten and 7th grade who  lacked proof
of having had chickenpox until 2004. Thus, the low uptake of
varicella vaccine in Minnesota resulted in the incidence of natu-
ral varicella remaining high well beyond 2001. Annual percentage
increases in HZ incidence among U.S. veterans reported by Rim-
land and Moanna [65] were lower than those found in Antelope
Valley. It is likely that some veterans sought treatment at non-
VA-facilities and some of those who  were eligible for Medicare
sought medical care in a private sector [65]. Furthermore, the
age distribution of those participating in the military differs from
that of the general U.S. population, preventing direct comparisons
between the two  cohorts [65,66]. Additionally, the increases in
HZ incidence reported by Cockrill among individuals in the U.S.
armed forces were also lower than those found in Antelope Val-
ley. These rates may  have also been inﬂuenced by the periodic
administration of varicella booster vaccines as well as differences
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n occupational and leisure activities relative to those in the general
opulation [66].
. The CDCs “evidence” that HZ incidence rates had not
ncreased
In 2002, Brisson et al., in a letter to the editor [67], criticized
he CDC study that reported decreasing trends in varicella from
995 to 2000 [2],  stating, “. . .Seward had reported only half the
tory; shingles incidence rates should surely be reported alongside
hickenpox incidence.” Seward’s response to this deﬁciency was  as
ollows:
Because the population sizes in the varicella active surveillance sites
are not sufﬁcient to monitor age-speciﬁc herpes zoster incidence,
the CDC has funded two other sites—Massachusetts Depart-
ment of Public Health and Group Health Cooperative (GHC)
in Seattle—to conduct population-based varicella and herpes
zoster surveillance and monitor age-speciﬁc incidence rates.
Massachusetts has monitored incidence through a statewide
telephone survey since 1998, while GHC is examining its auto-
mated medical records since 1992. To date, no increase in herpes
zoster is evident in any age group in either site (CDC, unpublished
data, 2001). [Italicization added for emphasis.] [67].
.1. The Massachusetts Department of Public Health Study lacked
tatistical power
The phone survey (not published in a peer-reviewed jour-
al) conducted by the Massachusetts Department of Public
ealth included only 4916 and 3123 respondents reporting HZ
ases among individuals aged 1–19 years in 1999 and 2000,
espectively—for a total of 7319 p-y. During an overlapping 2-
ear period 2000–2001, the AV-VASP study region, comprised
f 118,685 individuals in that same age group, accumulated a
otal observation time of 237,370 p-y, exceeding the Massachusetts
tudy by more than 30-fold.
Notably, the varicella-vaccination coverage level in this Mas-
achusetts study region was not as high as in the VASP study region.
hus, any increase in HZ incidence rates among the Massachusetts
tudy population would be expected to be lower in magnitude rel-
tive to the VASP study region where approximately 50% of all
hildren under 10 years of age had been administered the vaccine
y 2000 [29]. Further, the small sample size of the Massachusetts
tudy resulted in an unacceptably low statistical power to detect
hether or not an increase in HZ incidence had occurred. Thus, the
DC knew, or should have known, that its conclusion that there
ere “no increases in herpes zoster incidence” based on this Mas-
achusetts study was invalid.
able 3
omparison of reported varicella incidence rates (cases/1000) by age category reported by
ASP  [32].
Age category (years) GHC, Seattle, Washington 1992–1996 An
Varicella incidence rate % of NHIS rate Va
1–4 14.53b 14.5 91
5–9  8.2c 9.9 82
10–19  1.9c 15.6 10
Mean  % of NHIS rate – 13.3 –
a Ascertainment-corrected incidence rates from Antelope Valley VASP by Goldman [32
b Incidence rate given directly in GHC study results by Jumaan et al. [68].
c Incidence rate estimated from “Fig. 2” of GHC study by Jumaan et al. [68].e 31 (2013) 1680– 1694 1687
7.2. The GHC study showed increasing trends in HZ incidence
among adults and children during 2000–2002 when the varicella
incidence rate dramatically declined
The GHC study had an annual average enrollment of 350,000 of
all ages. It was similar to the 1995 population of 300,000 in the Ante-
lope Valley region, yet Seward et al., in an author reply to Brisson
et al., had indicated such population sizes were generally inade-
quate to monitor age-speciﬁc HZ incidence rates [67]. The GHC was
promoted as having an observation time of more than 3.9 million p-
y since varicella cases were tracked for 11 years, from 1992 to 2002,
in the GHCs administrative health-records database [68]. The HZ
incidence rates reported for the study population of all ages were
statistically not signiﬁcantly different in the pre- and post-varicella
vaccination periods when age-adjusted to the US  population in
2000 (an adjustment that was necessary because the number of
persons in each age group enrolled during the study period was
not constant).
The study reported that the age-adjusted HZ incidence rate
declined 14.2% from a peak of 4.05/1000 p-y in 1992 to a nadir of
3.47/1000 p-y in 2000. However, based on the data plotted in that
study’s “Fig. 1”, HZ incidence rates began to rise—increasing 8% from
the nadir in 2000 to about 3.75/1000 p-y in 2002 [68]. Interestingly,
ignoring the unexplained high HZ incidence rate shown in 1992
and evaluating the trend from 1993 and 1994 to the same nadir
point in 2000, the apparent HZ incidence rates decreased (approx-
imately 11% and 6% [mean 8.5%], respectively) at a slower annual
rate (1.8%/year and 0.86%/year, respectively) over 6–7 years relative
to the faster 8% (4%/year) increase in HZ incidence rates during 2001
and 2002. Further, as the GHC study’s authors admitted, the vacci-
nation rates in Seattle, Washington were lower than the national
average such that “few children [aged 0–9 years] had been vacci-
nated during 1996 and 1997” [68]. Yet, the reported age-speciﬁc
HZ incidence rate for the GHCs enrollment population increased
among both the vaccinated children (from “0” cases/100,000 p-y
in 1998–1999 to “49” cases/100,000 p-y in 2002) and the unvac-
cinated children (increasing nearly 70% from “87”/100,000 p-y in
1996 to “145”/100,000 p-y in 2002) [68].
The serious population-sample limitation of the GHC study was
conﬁrmed by the reported 1992–1996 varicella incidence rates of
14.54, 8.2, and 1.9 cases/1000 among children aged 1- to 4-years,
5- to 9-years, and 10- to 19-years, respectively, which were only
14.5%, 9.9%, and 15.6% of the respective “gold standard” 1990–1994
rates reported by NHIS in these same age categories (Table 3).
By contrast, the corresponding 1995 ascertainment-corrected inci-
dence rates from AV-VASP data were 91.5%, 99.8%, and 89.3% of the
reported NHIS incidence rates, respectively (Table 3) [32].
Thus, the GHC study was severely compromised by: (1)
extreme under-reporting of cases (without the ability to perform
ascertainment-correction), (2) a signiﬁcantly lower level of vacci-
nation coverage relative to the Antelope Valley communities under
active surveillance, (3) variability associated with the enrollment in
 the NHIS criterion standard with rates reported from GHC [68] and Antelope Valley
telope Valley VASP 1995 NHIS 1990–1994
ricella incidence ratea % of NHIS rate Varicella incidence rate
.9 91.5 100.4
.7 99.8 82.9
.85 89.3 12.15
 93.5 100.0
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he records-tracking data system of the GHC, a Health Maintenance
rganization (HMO), that was ever-changing over the 11-year
tudy period, and (4) selection bias due to such factors as cost of
nrollment and employers offering the HMO  plan. Therefore, the
onclusion that “the vaccination-associated decrease in varicella
isease did not result in an increase in the incidence of HZ”, drawn
rom the GHC study data, was based on selective endpoint data that,
iven the preceding factors, was, at best, only somewhat represen-
ative of HZ incidence rates in the sample population enrolled and,
herefore, could not be representative of true population trends
or HZ incidence rates. Ironically, although not achieving statistical
igniﬁcance, the data suggest that, beginning in the post-vaccine
ear 2000, when the varicella incidence rate ﬁnally declined to less
han 50% of the prior 1992–1999 mean rate, the age-adjusted HZ
ncidence rates (that included adults) increased through the 2002
tudy endpoint. Concomitantly, increasing HZ incidence rates were
peciﬁcally noted by the study’s authors among both vaccinated
nd unvaccinated children under 10 years of age.
.3. CDC promoted two poorly designed studies
In view of the preceding facts, the CDC had funded two different
tudies (Massachusetts Department of Public Health and GHC) hav-
ng fundamentally ﬂawed methodologies with the apparent intent
o dilute the AV-VASP ﬁndings and minimize the signiﬁcance of
ope-Simpson’s exogenous boosting hypothesis [7].
On September 2002, the 42nd Interscience Conference on
ntimicrobial Agents and Chemotherapy (ICAAC) sponsored by The
merican Society for Microbiology was held in San Diego, Califor-
ia. During the Symposium on Varicella-Zoster Virus from 8:30
o 11:00 a.m., Dr. John Edmunds presented, “Potential Changes in
oster Epidemiology with Childhood Immunization”. During the
uestion phase, Dr. Jane Seward was acknowledged and stated
ategorically that in the U.S., at the various active surveillance
ites, no increases had been seen in HZ incidence during the post-
accination years—quoting statistics from both the Massachusetts
epartment of Public Health and GHC studies.
Later in 2002, Roche [69] refers to a personal communication
rom Dr. Jane Seward and writes: “Despite concerns of a rise in
oster, active surveillance for herpes zoster in the USA sentinel sites
as not shown any change in herpes zoster incidence to date” [69].
gain, in a December 2002 Australian newsletter, Burgess writes,
There has been no change in the age-speciﬁc incidence of herpes
oster since the program started” [70]. Thus, CDC ofﬁcials were not
eporting the preliminary increases in HZ reported by the AV-VASP
Figs. 1 and 2).
In 2010, Australia also reported increases in HZ that started after
he introduction of varicella vaccination [71,72]. Notably, though
aricella vaccination was recommended in Australia in 2000, only
ince September 2003 had the vaccine been publicly funded for
se in all children at 18 months of age, which explained its delays
n ﬁnding HZ-case increases.
. Were increased HZ incidence rates among 10- to
9-year-olds comparable to increases found in
re-licensure studies?
Civen et al., in a VASP/CDC study presenting the cumulative
ncidence rate of HZ during 2000–2006 [37, “Table 1”], assumed
hat the AV-VASP had 100% enumeration of reported HZ cases.
he AV-VASP/CDC authors explained that the 63% increase in HZ
ncidence rates, from 35 cases reported in 2000 (59.5/100,000 per-
ons; 95% C.I. 42.7–82.9) to 64 reported in 2006 (96.7/100,000;
5% C.I. 75.7–123.6; p < 0.02) in the 10- to 19-year-olds [36] par-
lleled reported increases in other studies “even before varicellae 31 (2013) 1680– 1694
vaccine was  available” [36]. Yet the 31% increase during 1979–1997
reported by Brisson et al. [73] represented only a 1.6% annual
increase among adults—which was explainable in terms of the con-
tinually aging population. The approximate 35% increase in the HZ
incidence rate in the study by Ragozzino et al. during 1944–1959
(16 years) similarly yielded about a 2.2% annual increase that was
again typical of an aging population [8].  This in no way compared
with the 63% increase during 7 years or 9% mean annual increase
reported in an adolescent cohort by the AV-VASP.
9. Evidence in support of Dr. Hope-Simpson’s 1965
hypothesis
In the Civen et al. study of HZ incidence, VASP/CDC authors
conceded: “The possible reasons for this increased incidence [63%
among those 10–19 years of age] cannot be conﬁdently explained”
[36].
To explain the high incidence in this cohort, consider the ﬁnd-
ings published by Hope-Simpson in which the crude HZ incidence
rate reported in children aged <10 years is 74/100,000 p-y. This
rate was slightly more than half that of the next age category,
10–19 years, or 138/100,000 p-y [7].  However, since approximately
50% of the children under 10 years of age were still susceptible
to varicella and hence, not candidates for reactivation of HZ [31],
the true HZ incidence rate among only those children with a prior
history of varicella would have been approximately double the
reported crude HZ incidence rate or about 148/100,000 p-y. Thus,
the true HZ incidence rate was actually constant over the age
range 0–19 years, being approximately the same in both age cat-
egories, 0–9 and 10–19 years. For the next three decades, those
20–49 years of age, the rate approximately doubled again to about
250/100,000 p-y, and then doubled again to about 500/100,000 p-y
among adults aged 50–59 years [7].
Presuming Dr. Hope-Simpson’s hypothesis was correct, as
exogenous exposures diminished in an age category comprised
of individuals with a previous history of varicella, those indi-
viduals would increasingly reactivate with HZ at an incidence
rate approaching 500/100,000 p-y—the same rate currently found
among adults with relatively few opportunities for immunologic
boosting. Thus, the high HZ incidence rates in the post-licensure
period, especially among children with a previous history of natural
varicella, based on AV-VASP data [3,4,35] reported some 40 years
after the 1965 Hope-Simpson paper, supported the hypothesis,
“The peculiar age distribution of zoster may  in part reﬂect the fre-
quency with which the different age groups encounter cases of
varicella” [7].  Additionally, unvaccinated children with a previous
history of varicella may  have greater sensitivity to exogenous expo-
sures (boosting) and a poorer cell-mediated response following
primary infection relative to older age groups. Thus, once adoles-
cents and adults are exposed to VZV, they remain boosted for longer
periods [4].  Table 1 indicates that the ascertainment-corrected rate
of 446/100,000 p-y among children aged <10 years with a previous
history of natural varicella had already approached the apparent
rate limit observed in older adults.
Moreover, the study in Japanese pediatricians aged 50–69 years
[50] demonstrated the Hope-Simpson hypothesis in the reverse
direction—whereby the relatively high HZ incidence that charac-
terizes adults was found to be as low as the pre-licensure rate in
children or adolescents due to the physicians’ frequent exogenous
exposures to children with natural varicella.Of course, elderly adults both the pre- and post-licensure peri-
ods continue to experience a sharp increase in HZ incidence rates
due to an age-related immune-system decline that begins at around
60 years and older [6].
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0. Studies of the cost-effectiveness of the US universal
aricella vaccination program
In 1994, Lieu et al. modeled the cost-effectiveness of a routine
aricella vaccination program for US children. From a medical per-
pective alone, varicella vaccination was not cost effective since the
nnual vaccination costs of approximately $162 million exceeded
he annual medical cost savings of $80 million (i.e., from the health
ayer perspective, $2 was spent for each $1 saved). However, by
onsidering the cost of a parent’s absence from work to care for
 child with varicella, estimated at $392 million annually, single-
ose varicella vaccination was now justiﬁed as being cost-effective
rom this societal perspective [74].
The preceding historical cost-effectiveness study was based on
our key, but incorrect, assumptions: (1) vaccination cost is $35.00
er dose with only a $5.00 administration fee, (2) a single vaccine
ose would confer life-long immunity, (3) vaccine efﬁcacy would
e high (85–95%) with negligible costs attributed to adverse effects
ssociated with the varicella vaccine, and (4) universal varicella
accination had no adverse effect on the occurrence of the closely
elated HZ in older individuals who had had natural varicella or on
hose who were administered the varicella vaccine.
The preceding assumptions all turned out to be seriously ﬂawed.
irst, after FDA approval, the vaccine pricing has increased to nearly
ouble the modeled cost. Moreover, as varicella vaccination cov-
rage increased, a single vaccine dose was found to no longer
onfer long-term protection from either natural or vaccine-strain
ZV infection. Additionally, HZ incidence rates were increasing in
he near absence of the natural boosting that previously occurred
n communities with annual varicella epidemics. For infants, the
pdated recommendation was that the ﬁrst dose be given at age
2 months with a second (booster) dose given at age 4–6 years
56]. Based on these revisions to vaccine cost and number of doses
lone, there was a fourfold increase in the annual cost of vaccina-
ion initially modeled by Lieu et al.—from $162 million to about
650 million—signiﬁcantly offsetting the projected combined cost
avings from both the medical and the societal perspectives.
Earlier, in 1999, Schuette and Hethcote developed a computer
imulation model to evaluate the effects of a vaccination program
or varicella using parameters estimated from epidemiological
ata. This simulation, which acknowledged discussions on vari-
ella and HZ with John Glasser at the National Immunization
rogram CDC, concluded, “zoster incidence increases in the ﬁrst
hree decades after initiation of a vaccination program” [75].
Prior to the licensure of a varicella vaccine, two UK university
esearchers, Garnett and Grenfell, had examined the implications of
 universal varicella vaccination program and, in 1992, concluded,
Under some conditions, mass application of such vaccines may
ave the impact of increasing herpes zoster incidence.  . .”  [76].
Many updated cost–beneﬁt analyses and studies of reduced
orbidity and mortality focus on outcomes involving solely
aricella—entirely ignoring the negative impact on HZ epidemiol-
gy [28,77,78].  Thus, both US and foreign studies still promote their
awed conclusion that such studies “conﬁrm the positive impact
f universal varicella vaccination” [79,80].
In 2005, Zhou of the National Immunization Program (NIP)
erformed an economic evaluation of the universal varicella vac-
ination program that included HZ in vaccinees and outbreak
anagement costs, but excluded increasing HZ among those with
 previous history of varicella and “potentially higher future
ost-vaccination incidence due to further accumulation of suscep-
ible persons and future outbreaks” [81]. This study concluded,
compared to the one-dose program, the two-dose program may
ot be cost effective” [81].
By contacting the Elsevier life science editor, the CDC suc-
eeded in having the journal Vaccine postpone a publication titled,e 31 (2013) 1680– 1694 1689
“Cost–beneﬁt analysis of varicella taking into account the closely
related herpes-zoster epidemiology”, which was accepted October
4, 2003. This computer model, without even addressing the costs
of serious adverse reactions to the varicella vaccine, reported that
universal varicella vaccination had the impact of an additional 14.6
million HZ cases (or 42% increase) among adults aged <50 years
during a 50-year period at a substantial medical cost burden of
$4.1 billion or $80 million annually utilizing a very conservative
estimated mean healthcare provider cost of $280 per HZ case [82].
After an attorney intervened, the paper was  ﬁnally published and
made available online on January 22, 2005.
11. Varicella vaccine efﬁcacy declines rapidly after the
“honeymoon” period
Vaccine efﬁcacy refers to the effectiveness of a vaccine to pre-
vent disease. In 1995, the CDCs ACIP claimed, “In clinical trials,
the vaccine has proven to be effective for greater than 10 years in
preventing varicella” [83]. Other reports suggested varicella vac-
cine confers long-lasting immunity of up to 20 years as shown in a
Japanese study [84]. However, only 1 in 5 (20%) children were vacci-
nated in Japan so that incidence of natural varicella cases remained
high, thus providing immunologic boosting to vaccinees when they
contacted or were exposed to children shedding varicella [85]. In
1995, Merck & Co., the US vaccine’s manufacturer, admitted that a
boost in antibody levels had been observed in vaccinees following
exposure to natural varicella, which could account for the apparent
long-term persistence of antibody levels after vaccination and “the
duration of protection from varicella obtained using Varivax in the
absence of wild-type boosting is unknown” [86].
During the ﬁrst years following licensure of the varicella vac-
cine, vaccine efﬁcacy based on studies in clinical practices [87,88]
and outbreaks in daycares and school settings [89–91] ranged from
70% to 100%. However, Galil et al. reported a 44% (95% C.I. 6.9–66.3%)
effectiveness of the vaccine in a varicella outbreak among 25 (28%)
of 88 children (in a daycare center between December 1, 2000, and
January 11, 2001, having a high proportion of vaccinated individ-
uals) [92]. Similarly, Lee et al. reported a 56% (95% C.I. 32.0–71.2%)
effectiveness in an outbreak involving a primary breakthrough case
followed by 54 cases in which 29 (53%) had been vaccinated in a
Minnesota school with an enrollment of 319 students in 2004 [93].
When exogenous exposures (boosts) became rare, the vaccine
was  less effective and children soon needed a booster varicella vac-
cination. In 2002, Gershon suggested, “the time for exploring the
possibility of routinely administering two  doses of varicella vaccine
to children seems to have arrived” [94]. In a 2004 study by the Epi-
demic Intelligence Service of the Centers for Disease Control and
Prevention (CDC), the reported Varivax vaccine efﬁcacy was  72%
(95% C.I. 3–87%) [95]. Wide conﬁdence intervals have character-
ized most outbreak investigations because of the relatively small
numbers of varicella cases in children that are associated with any
given local outbreak.
The AV-VASP investigated the secondary attack rate among
household contacts aged 1–14 years during 1997–2001 [96]. That
report states, “we  analyzed the secondary attack rate by year; ﬁnd-
ing no trend, we conducted subsequent analyses for the 5 year
period” [96]. That study’s ﬁndings of a single mean efﬁcacy of 78.9%
(95% C.I. 69.7–85.3%) using contacts aged 1–14 years [96] concealed
the discovery of a more than 20% decline in varicella vaccine efﬁcacy
by 2001 as the level of vaccination increased [4].  Although the 20%
decline in vaccine efﬁcacy from 1999 to 2001 was  not statistically
signiﬁcant at the 95% conﬁdence level (z = 1.96), it was  signiﬁcant
at the 94% conﬁdence level (z = 1.88). By July/August 2002, the vari-
cella vaccine’s one-dose efﬁcacy had declined to 58.4% (95% C.I.
13.7–79.9%) which was  statistically signiﬁcantly lower than the
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Table 4
Varicella vaccine efﬁcacy among household contacts by year, 1997–2002, Antelope
Valley VASP [4] and mean efﬁcacy 1997–2002 [96].
Year of study Vaccine efﬁcacy stratiﬁed
by yeara % (95% C.I.)
Mean vaccine efﬁcacyb
% (95% C.I.)
1997 87 (75–93)
78.9
(69.7–85.3)
1998 94 (83–98)
1999 96 (83–99)
2000 86 (74–92)
2001 74 (58–84)
2002c 58 (14–80) –
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oBased on household contacts aged <20 years [4].
b Based on household contacts aged 1–14 years [96].
c Partial year of data collection through August 2002.
eak 1999 efﬁcacy [4] (Table 4). The one-dose vaccination program
sing Varivax demonstrated peak efﬁcacy in 1999 (known as the
honeymoon” effect) because vaccinated children had just recently
een boosted by the outbreaks of varicella that were occurring in
he community at that time.
2. Safety of varicella and HZ vaccinations
2.1. Complications of introducing the vaccine- or Oka-strain
aricella zoster virus (VZV)
Consider a child that is administered the live Oka-strain vari-
ella vaccine and is subsequently exposed to an individual shedding
ZV—either: (a) a child with varicella or HZ infection or (b) an adult
ith HZ infection. If the VZV strains are sufﬁciently heterologous
genetically distinct), a second case of varicella can result. There
re at least ﬁve VZV genotype variations or virus clades known
t this time, in addition to 4 rarely-reported provisional clades.
symptomatic reinfection of a second strain can occur and establish
atency, thus increasing the potential for HZ since both strains are
ubject to reactivation [97–99].  One study documents the trans-
ission of a new VZV strain comprised of a marker exclusively
haracteristic of the Oka-strain in a wild-type isolate [100].
2.2. Reported adverse reactions and complications of live-virus
aricella vaccination
Initial modeling of the cost effectiveness of universal vari-
ella vaccination program assumed that vaccinated individuals
ould incur negligible adverse vaccine reactions and thus,
accine-associated medical costs were not included in any of
he models [74–82].  However, numerous published case studies
ocument a wide range of deleterious outcomes in immuno-
ompetent individuals following varicella (Oka-strain) vaccination
f children or HZ vaccination of adults. Some of the adverse
utcomes include ocular complications (e.g., blurred vision, her-
es zoster ophthalmicus—HZO, visual loss or acute posterior
ultifocal pigment placoid epitheliopathy—APMPPE, interstitial
eratitis, etc.) [101–108], central nervous system disease (e.g.,
ncephalitis, acute disseminated encephalomyelitis—ADEM, acute
erebellar ataxia, VZV meningitis) [99,105,109–119], skin rash
e.g., urticaria, thrombocytopenic pupura, etc.) [120–123], HZ reac-
ivation (including disseminated HZ and acyclovir-resistant HZ)
116,124–131], stroke following vaccination (varicella vasculopa-
hy) [132], secondary transmission (to other children, adults,
regnant mothers) [133–136], pneumonia [137], varicella infec-
ion (i.e., breakthrough varicella) [138–140], decreasing immunity
141,142],  Stevens–Johnson syndrome [143], fatal outcomes (e.g.,
hild with acute lymphoblastic leukemia, fetal tissue calciﬁca-
ions and hydrops) [144,145],  autoimmune disorders [142], and
ther miscellaneous reactions (e.g., reactions to gelatin, large locale 31 (2013) 1680– 1694
reactions, prolonged viremia, outbreak among school children that
received 1- and 2-doses, and hematologic disease) [146–151].
Morbidity of even rare serious adverse events reported after
varicella vaccination (some of which were enumerated in the pre-
ceding paragraph) contribute to offsetting the beneﬁts of varicella
vaccination [117]. In 2008, Chaves et al. reported that 15–20%
of children who  received one dose of varicella developed break-
through varicella when exposed to VZV, some of which resulted
in complications comparable to those occurring in unvaccinated
individuals [26].
12.3. Anecdotal reports from parents reporting children
experiencing multiple HZ cases
The following anecdotal reports from parents demonstrate
the challenges associated with diagnosing and treating children
experiencing multiple HZ reactivations. Interestingly, both US and
foreign studies demonstrating reductions in varicella morbidity
since the start of universal varicella vaccination [18,25,79,80] have
excluded the analysis of rising morbidity from increasing cases
of HZ. These studies may  have inappropriately excluded this ris-
ing HZ-associated morbidity because the HZ medical costs far
outweighed any projected savings from reduced varicella morbid-
ity.
Case 1: “My  daughter [‘Sarah’—name changed for conﬁdential-
ity] has suffered from recurring childhood shingles since January
2003. Her last episode has just been resolved in early September
2004, because I was ﬁnally able to get her on the right antiviral
medication with the proper dosage. Sarah was seen by two pediatri-
cians, one allergist and two dermatologists, including one of the top
pediatric dermatologists in our nation. Perhaps because childhood
shingles is so rare, her case was  misdiagnosed as atopic dermatitis.
The treatment for this condition, as you know, includes baths to
keep the skin moist and topical agents to keep it lubricated. This
only worsened Sarah’s viral sores.”
“Sarah was prescribed 23 different oral and topical medica-
tions, including many doses of cortisone and antihistamines in
20 months. From the onset, I felt that my daughter’s condition
was  systemic. It was  only through my  research and relentless
questioning that lab-work was done. In July 2004, Sarah’s blood-
work showed elevated levels of varicella-zoster virus. Although the
physician she was working with at the time felt this was the result
of her having chickenpox when she was two, I upon learning she
could and should be re-tested within a month, requested this test.
Her blood levels [of zoster] virus had nearly doubled.”
“. . .I  am writing to you with the hope that you can help educate
and advocate for this information to be made more available to the
general public. As rare as childhood shingles is, by not catching this
early on through the proper tests and the proper prescriptions for
treatment, my  daughter has suffered terribly. She now has post-
herpetic neuralgia (PHN) as well. . .”
Case 2: On November 5, 2007, parents of a daughter with shin-
gles reported: “. . .Our oldest daughter who is only 16 recently
suffered from her second bout with shingles. She ﬁrst had an
episode of shingles at the age of 13. Our daughter NEVER had
chickenpox, but was given the varicella vaccine in 1995. We  were
never told or even warned that it could cause shingles. We  ﬁnd
it unbelievable that the ‘solution’ we  are being provided is to go
to the Infectious Disease Department at a local University Hospi-
tal in order to have them ‘help us manage’ this for the rest of our
daughter’s life. Now we have to remedy the shingles and we  are
altogether convinced that there will be many, many other young
people adversely affected by what is a dangerous vaccine with
awful side effects that stay with you for a lifetime. . .far worse than
chickenpox in one’s youth. Our daughter missed a week of school
each time and suffered incredibly.  . .”
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Case 3: On September 22, 2008, a nurse contacted Goldman to
hare the following experience: “My  son, who had natural chick-
npox at 3 years of age, and who is now 16 years old, has been
ecovering for the past 6½ months from herpes zoster (with a
ash in the T1 dermatome). He experienced vomiting and severe
eadaches that lead to a diagnosis of viral meningitis from central
ervous system (CNS) complications of herpes zoster.”
Interestingly, the nurse indicated that the physician treating her
on had encountered another teen with the same diagnosis a week
rior to her son’s case.
3. Costs to prevent HZ and post-herpetic neuralgia
In 2011, the FDA approved Merck’s Zostavax® for adults aged
0 years and older, but the CDC has, thus far, declined to recom-
end it for mass use. In late 2007, the CDCs ACIP recommended
hat the Zostavax vaccine, originally approved and licensed by the
DA in 2006, be given to all adults aged 60 years and older. Admin-
stering it is claimed to provide a boost to the adult immune system
hat helps to suppress or postpone the onset of HZ. However, nat-
ral boosts were previously available at no cost to adults from
heir periodic exposures to children who were actively shedding
ZV in the community. Thus, the shingles vaccine raises the issue
f not only achieving weak protective outcomes in adult vaccina-
ions, but adults also tend to experience a higher rate of adverse
accination effects relative to children, including a higher rate of
erious adverse effects (possibly due to the 14-fold higher plaque
orming units [pfu], or 19,000 pfu, relative to the varicella vaccine’s
400 pfu).
Based on the randomized, double-blind, placebo-controlled HZ
rial by Oxman et al. which tracked 38,546 healthy subjects aged
0 years and older (median age 69 years) for a mean duration of
.13 years [152] and using the current cost of about $200 per dose
based on the Rite Aid® or Walgreens pharmacy fee), the costs per
ear to prevent one case of HZ and one case of PHN were, respec-
ively: $35,000 (where number needed to vaccinate, NNV = 175)
nd $217,400 (where NNV = 1087) [153].
The placebo group (without exogenous boosting or those not
dministered the HZ vaccine) demonstrated an HZ incidence rate
f 11.12 cases/1000 p-y, approximately 100% higher than the HZ
ncidence rate of 5.42 cases/1000 p-y among the cohort receiving
he HZ vaccine [152]. Unfortunately, once the level of exogenous
oosting diminished in the AV-VASP community via universal
aricella vaccination, this same 100% increase in adult HZ inci-
ence was observed in the surveillance data in the post-vaccine
eriod relative to the adult HZ incidence in the pre-licensure
ra.
Interestingly, Brisson, using parameters obtained from the same
xman study, assuming no waning of vaccine protection, and using
 different, more conservative deﬁnition of NNV, estimates for
dults 65 years and older that the NNV to prevent one case of HZ and
ne case of PHN over their lifetime is 11 and 43, respectively [154].
sing 20% per year waning of vaccine efﬁcacy (average duration
f 5 years), Brisson estimates a higher NNV of 41 (correspond-
ng to $8200) and 229 (corresponding to $45,800), respectively
154].
4. Lack of understanding the human immune system
The human immune system is not fully understood—in fact man
nderstands only the fringes of this complex system that involves
uch more than a balance between Th1 and Th2 responses in a
ystem where there are more than 17 identiﬁed types of T cells
bone marrow immune-system cells [B cells] that mature in the
hymus gland) [155,156].e 31 (2013) 1680– 1694 1691
Canniff et al. reported an association between those individ-
uals with clinical or laboratory evidence of varicella-zoster virus
(VZV) infection and lower risk of glioma [157], suggesting a protec-
tive effect of VZV against glioma [158,159].  The authors explained,
“The protective effect of prior VZV infection against the incidence
of glioma may  be mediated by cytotoxic T lymphocytes (CTL) that
recognize epitopes shared by VZV and glioma cells” [157].
In addition, Posner found that both the genetic background and
previous immunological history of an individual play important
roles in determining whether a person will be either: (a) protected
from or (b) susceptible to adverse reactions caused by his or her
exposure to viral antigens [160].
Further, Silverberg et al. also reported that wild-type VZV infec-
tion up to 8 years of age was found to be protective against atopic
disorders that are thought to be “mediated by suppression of IgE
production and allergic sensitization, as well as altered leukocyte
distributions” [161].
Unfortunately, it is not possible to fully estimate the nega-
tive repercussions of the universal varicella vaccination program
on such natural-chickenpox-protective outcomes as mentioned
above.
15. Conclusion
Prior to the universal varicella vaccination program, 95% of
adults experienced natural chickenpox [162] (usually as pre-school
to early elementary school children)—these cases were usually
benign. In the prelicensure era, the periodic exogenous boost-
ing that adults received from those shedding VZV resulted in
long-term immunity. This high percentage of seropositive indi-
viduals and their long-term immunity have been compromised
by the universal varicella vaccination of children which provides
at best 70–90% protection [142,163–166] that is temporary and
of unknown duration—shifting chickenpox to a more vulnerable
adult population which, as Dr. Jane Seward cautioned in 2007, car-
ries 20 times more risk of death and 10–15 times more risk of
hospitalization compared to chickenpox in children [167]. Thus,
the proponents for universal varicella vaccination have failed to
consider increased HZ-related morbidity as well as the adverse
effects of both the varicella and HZ vaccines which have more than
offset the limited beneﬁts associated with reductions in varicella
disease. The universal varicella (chickenpox) vaccination program
now requires a booster vaccine for children and an HZ vaccine to
boost protection in adults. However, these are less effective than
the natural immunity that existed in communities prior to licensure
of the varicella vaccine. Hence, rather than eliminating varicella
in children as promised, routine vaccination against varicella has
proven extremely costly [60,62,168] and has created continual
cycles of treatment and disease.
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